wean off effexor
Some of these drugs (i.e., bupropion, mirtazapine, nefazodone, trazodone, trimipramine) appear to have a modest or minimal effect on REM sleep.
Cardiovascular
There are reports of sustained hypertension (some requiring immediate treatment). There have been postmarketing reports of toxic epidermal necrolysis.
One case of venlafaxine-induced Stevens-Johnson syndrome has been reported. This increase was duration dependent over wean off effexor study period and tended to be greater with higher doses. Although these events occurred during treatment with venlafaxine, causality has not been determined.
Respiratory
Respiratory side effects have frequently included pharyngitis, sinusitis, and yawning.
Respiratory side effects reported in premarketing Phase 3 trials have included increased cough, dyspnea, asthma, chest congestion, epistaxis, hyperventilation, laryngismus, laryngitis, pneumonia, voice alteration, atelectasis, hemoptysis, hypoventilation, hypoxia, larynx wean off effexor pleurisy, pulmonary embolus, and sleep apnea. Untoward events associated with this exposure were recorded by clinical investigators using terminology of their own choosing. Although these events occurred during treatment with venlafaxine, causality has not been determined. Consequently, it is not possible to provide a meaningful estimate of the proportion of individuals experiencing adverse events without first grouping similar types of untoward events into a smaller number of standardized event wean off effexor the tabulations that follow, reported adverse events were classified using a standard COSTART-based Dictionary terminology. Experience with the immediate-release venlafaxine showed that sustained hypertension was dose-related, increasing from 3% wean off effexor 7% at 100 to 300 mg/day to 13% at doses above 300 mg/day. The manufacturer recommends that therapy be discontinued in patients who develop seizures.
The impact of venlafaxine on pain summation may indicate a potential analgesic effect for clinical neuropathic pain.
Nearly all selective serotonin reuptake inhibitors, mixed serotonin/norepinephrine reuptake inhibitors, and tricyclic antidepressants cause sleep abnormalities to some extent. Although these events occurred during treatment with venlafaxine, causality has not wean off effexor determined. Although these events occurred during treatment with venlafaxine, causality has not been determined.
Although rare, interstitial pneumonitis secondary to venlafaxine therapy has been reported. ough increased, and dysmenorrhea3.
— Incidence less than 1%.
2 Incidence based wean off effexor number of male patients.
3 Incidence based on number of female patients.
Body wean off effexor a Whole
Headache
25%
24%
Asthenia
12%
6%
Infection
6%
5%
Chills
3%
—
Chest pain
2%
1%
Trauma
2%
1%
Cardiovascular
Vasodilatation
4%
3%
Increased blood pressure/hypertension
2%
—
Tachycardia
2%
—
Postural hypotension
1%
—
Dermatological
Sweating
12%
3%
Rash
3%
2%
Pruritus
1%
—
Gastrointestinal
Nausea
37%
11%
Constipation
15%
7%
Anorexia
11%
2%
Diarrhea
8%
7%
Vomiting
6%
2%
Dyspepsia
5%
4%
Flatulence
3%
2%
Metabolic
Weight loss
1%
—
Nervous System
Somnolence
23%
9%
Dry mouth
22%
11%
Dizziness
19%
7%
Insomnia
18%
10%
Nervousness
13%
6%
Anxiety
6%
3%
Tremor
5%
1%
Abnormal dreams
4%
3%
Hypertonia
3%
2%
Paresthesia
3%
2%
Libido decreased
2%
—
Agitation
2%
—
Confusion
2%
1%
Thinking abnormal
2%
1%
Depersonalization
1%
—
Depression
1%
—
Urinary retention
1%
—
Twitching
1%
—
Respiration
Yawn
3%
—
Special Senses
Blurred vision
6%
2%
Taste perversion
2%
—
Tinnitus
2%
—
Mydriasis
2%
—
Urogenital System
Abnormal ejaculation/ orgasm
12%2
—2
Impotence
6%2
—2
Urinary frequency
3%
2%
Urination impaired
2%
—
Orgasm disturbance
2%3
—3
Dose Dependency of Adverse Events
A comparison of adverse event rates in a fixed-dose study comparing Effexor (venlafaxine hydrochloride) 75, 225, and 375 mg/day with placebo revealed a dose dependency for some of the more common adverse events associated with Effexor use, as shown in the table that follows. Dermatologic side effects reported in premarketing Phase 3 trials have included pruritus, acne, alopecia, contact wean off effexor dry skin, eczema, maculopapular rash, psoriasis, urticaria, brittle nails, erythema nodosum, exfoliative dermatitis, lichenoid dermatitis, hair discoloration, skin discoloration, furunculosis, hirsutism, leukoderma, miliaria, petechial rash, pruritic rash, pustular rash, vesiculobullous rash, seborrhea, skin atrophy, skin hypertrophy, skin striae, and decreased sweating. There have been reports of increases in prothrombin time, partial thromboplastin time, or INR when venlafaxine was given to patients receiving warfarin therapy.
Top
Side Effects by Body System
Gastrointestinal
Gastrointestinal side effects wean off effexor frequently included nausea (up to 35%), dry mouth (14% to 18%), constipation (12%), anorexia (12% to 23%), vomiting, diarrhea (5% to 12%), eructation, abdominal pain, and flatulence.
Gastrointestinal side effects reported in premarketing Phase 3 trials have included increased appetite, bruxism, colitis, dysphagia, tongue edema, esophagitis, gastritis, gastroenteritis, gastrointestinal ulcer, gingivitis, glossitis, rectal hemorrhage, hemorrhoids, melena, oral moniliasis, stomatitis, mouth ulceration, abdominal distention, biliary pain, cheilitis, cholecystitis, cholelithiasis, esophageal spasms, duodenitis, hematemesis, gastroesophageal reflux disease, gastrointestinal hemorrhage, gum hemorrhage, hepatitis, ileitis, jaundice, intestinal obstruction, liver tenderness, parotitis, periodontitis, proctitis, rectal wean off effexor salivary gland enlargement, increased salivation, soft stools, and tongue wean off effexor system
Nervous system side effects have frequently included dizziness (16%), somnolence (up to 14%), insomnia (11% to 25%), fatigue (11%), nervousness (9%), abnormal dreams, sleep abnormalities, tremor, depression, paresthesia, decreased libido, agitation, hypertonia, anxiety, delirium, and twitching. Although these events occurred during treatment wean off effexor venlafaxine, causality has not been determined.
Psychiatric
Psychiatric side effects have included visual hallucinations, hypomania, and mania.
Psychiatric side effects reported in premarketing Phase 3 trials have included emotional lability, delusions, euphoria, hallucinations, manic wean off effexor psychosis, suicidal ideation, abnormal/changed behavior, homicidal ideation, paranoid reaction, and psychotic depression. The same study reported an increase in the average pulse rate of 1.1 wean off effexor 4.5 beats per minute.
Another study (n=7) suggests that venlafaxine may promote adverse cardiovascular and cerebrovascular events by increasing platelet activity in susceptible wean off effexor increase in heart rate of 4 beats per minute has been reported.
According to a retrospective review, in the overdose setting (up to 3 g of venlafaxine), tachycardia, hypertension, mydriasis, QTc prolongation, and transient arrhythmia can be expected. Although these events occurred during treatment with venlafaxine, causality has not been determined.
A case of dose-related increase of intraocular pressure caused by venlafaxine use has been reported.
Metabolic
Metabolic side effects wean off effexor included weight loss (3%).
Metabolic side effects reported in premarketing Phase 3 trials have included weight gain, increased alkaline phosphatase, dehydration, hypercholesteremia, hyperglycemia, hyperlipemia, hypoglycemia, hypokalemia, increased SGOT (AST), increased SGPT (ALT), thirst, bilirubinemia, increased BUN, increased creatinine, diabetes mellitus, glycosuria, gout, abnormal healing, wean off effexor hypercalcinuria, hyperkalemia, hyperphosphatemia, hyperuricemia, hypocholesteremia, hyponatremia, hypophosphatemia, hypoproteinemia, and uremia. Following discontinuation of venlafaxine, symptoms resolved within approximately 72 hours. Untoward events associated with this exposure were recorded by clinical investigators using terminology of their own choosing. Dyskinesia has also been reported.
Venlafaxine has been reported to increase the pain tolerance threshold to electrical sural nerve stimulation and the threshold at which pain increases (pain summation).
One wean off effexor of serotonin syndrome has been reported which is believed to have been precipitated by the combination of venlafaxine and trazodone.
One small study has suggested that venlafaxine may improve attention, concentration, memory, and reaction time performance after single oral doses.
Nervous system side effects reported in wean off effexor Phase 3 trials have included amnesia, confusion, depersonalization, hypesthesia, abnormal thinking, trismus, vertigo, akathisia, apathy, ataxia, circumoral paresthesia, central nervous system (CNS) stimulation, hostility, hyperesthesia, hyperkinesia, hypotonia, incoordination, myoclonus, neuralgia, neuropathy, seizure, abnormal speech, stupor, adjustment disorder, akinesia, alcohol abuse, wean off effexor bradykinesia, buccoglossal syndrome, cerebrovascular accident, feeling drunk, loss of consciousness, dementia, dystonia, increased energy, facial paralysis, abnormal gait, Guillain-Barre Syndrome, wean off effexor hypokinesia, hysteria, impulse control difficulties, increased libido, motion sickness, neuritis, nystagmus, paresis, decreased or increased reflexes, and torticollis. Symptoms can be minimized by slow tapering or switching to a drug with a longer half-life (e.g., fluoxetine).
Online pharmacy Tags
78 79 80 81 82 83 84 85 86
.